Clinical Trials Logo

Clinical Trial Summary

Acute ST segment elevation myocardial infarction (STEMI) has a high disability mortality rate, and timely reperfusion treatment can significantly reduce the mortality of patients. Emergency PCI is the preferred strategy for STEMI treatment recommended by domestic and international guidelines. The long-term existence of stents can never completely avoid the formation of thrombosis in the stents and affect the relaxation and contraction of criminal blood vessels. Drug coated balloon provides a new concept and technology of interventional therapy for coronary artery disease in the form of "intervention without implantation". Through balloon dilation of local blood vessels to release anti proliferative drugs to coronary artery wall and inhibit intimal hyperplasia, it can not only treat serious coronary artery disease, improve coronary blood supply and vascular function, but also not leave permanent implants in the blood vessels; The main pathogenesis of STEMI is thrombosis based on the rupture or erosion of coronary atheromatous plaque. In terms of pathophysiological mechanism, drug coated balloons are also suitable for STEMI patients without obvious thrombosis or severe dissection after full pretreatment. The two-dimensional lumen images obtained by traditional coronary angiography can not directly reflect the vessel wall, so we can not evaluate the actual size of the vessel, plaque characteristics and the effect of intervention through coronary angiography; Optical coherence tomography (OCT) uses near-infrared scanning to produce high-resolution tissue microscopic images with a resolution of up to 10 μ m. It can clearly observe the three-layer structure of coronary artery, find abnormal intima structure, and more clearly identify thrombosis, dissection, plaque erosion or collapse in coronary artery, providing more valuable information for optimizing interventional treatment. Therefore, the application of drug coated balloon under the guidance of OCT in STEMI can provide a more accurate and optimized diagnosis and treatment scheme for STEMI patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05680051
Study type Interventional
Source Henan Institute of Cardiovascular Epidemiology
Contact Junhui Zhang, Dr
Phone +86 0371 58681033
Email 09junhuizhang@163.com
Status Recruiting
Phase N/A
Start date January 30, 2023
Completion date February 28, 2025

See also
  Status Clinical Trial Phase
Completed NCT04628377 - Prognostic Implication of Angiography-Derived IMR in STEMI Patients
Recruiting NCT02507128 - Effects of Glucagon Like Peptide-1 on No-reflow N/A
Terminated NCT04571580 - Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention Phase 3
Completed NCT01930682 - EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction Phase 4
Recruiting NCT04861389 - Distal Transradial Access for Primary Percutaneous Coronary Intervention in STEMI Patients N/A
Withdrawn NCT02405130 - The RESTORE-SIRIO Randomized Controlled Trial N/A